The disclosure provides a minimal antigen delivery system consists essentially of PEGylated stealth liposomes loaded with an immunogenic human leukocyte antigen (HLA) class restricted peptide and surface modified with a cell targeting peptide which mediates binding and internalization of the liposomes into a target cell. Further disclosed are a HLA class 1 restricted peptide that is measles virus hemagglutinin peptide H250 and a cell targeting peptide that is H 1299.3 for targeting cancer cells.
